Patents Examined by Erinne R Dabkowski
-
Patent number: 10967048Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.Type: GrantFiled: January 26, 2016Date of Patent: April 6, 2021Assignee: Lubris LLCInventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed
-
Patent number: 10968266Abstract: Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.Type: GrantFiled: September 7, 2015Date of Patent: April 6, 2021Assignee: UNIVERSITY OF COPENHAGENInventors: Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Jens Juul Holst, Filip Krag Knop, Mikkel Bring Christensen, Lærke Smidt Gasbjerg
-
Patent number: 10952940Abstract: Reagents and methods for whitening and remineralizing teeth using biomineralizing peptides are described.Type: GrantFiled: January 13, 2017Date of Patent: March 23, 2021Assignee: University of WashingtonInventors: Mehmet Sarikaya, Sami Dogan, Hanson Fong, Deniz Yucesoy
-
Patent number: 10947279Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: GrantFiled: May 1, 2019Date of Patent: March 16, 2021Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Patent number: 10941182Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: GrantFiled: June 10, 2015Date of Patent: March 9, 2021Assignee: Amgen Inc.Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Patent number: 10933116Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: GrantFiled: June 24, 2016Date of Patent: March 2, 2021Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Patent number: 10925954Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.Type: GrantFiled: April 18, 2018Date of Patent: February 23, 2021Assignee: Statens Serum InstitutInventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
-
Patent number: 10919939Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: April 3, 2017Date of Patent: February 16, 2021Assignees: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Patent number: 10905736Abstract: In various embodiments, ezetimibe-associated apoA-I mimetic peptide are provided that show improved synergistic activity between ezetimibe and the apoA-I peptide in vivo. In certain embodiments the peptide component is a transgenic 6F and the ezetimibe-associated apoA-I mimetic peptide is an Ez-T6F peptide. Methods of making the Ez-apoA-I peptides are also provided. In certain embodiments the methods involve incubating ezetimibe and an apoAI mimetic peptide (e.g., T6F) in a solution comprising ethyl acetate and acetic acid or in a solution comprising ethyl lactate and lactic acid; and drying the solution to provide a dry ezetimibe-associated apoA-I mimetic peptide.Type: GrantFiled: September 12, 2017Date of Patent: February 2, 2021Assignee: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Srinivasa T. Reddy, Mohamad Navab
-
Patent number: 10899793Abstract: Certain embodiments of the invention provide a compound of formula (I): R1—C(?O)—W—X—Y—Z—N(R2)2??(I) or a salt thereof, wherein R1, R2, W, X, Y and Z are as defined herein, as well as methods of use thereof.Type: GrantFiled: May 25, 2017Date of Patent: January 26, 2021Assignees: Regents of the University of Minnesota, Torrey Pines Institute for Molecular StudiesInventors: Carrie Haskell-Luevano, Skye Ross Doering, Jon R. Appel, Marc A. Giulianotti, Richard A. Houghten, Clemencia Pinilla, Radleigh G. Santos
-
Patent number: 10888616Abstract: This invention relates to ready-to-use and safe solution compositions of glucagon suitable for administration by manual injection or by an insulin pump or other injection device to treat hypoglycemia. Said compositions comprise glucagon, an acid, anti-gelling polyol, a stabilizing-salt, viscosity reducer and an antioxidant, have a final pH between about 2 and 5, and is gel-free, chemically-stable, and pump-able.Type: GrantFiled: February 22, 2018Date of Patent: January 12, 2021Assignee: LATITUDE PHARMACEUTICALS, INC.Inventors: Hailiang Chen, Andrew Xian Chen, Norman Keith Orida
-
Patent number: 10870783Abstract: Provided herein is a surfactant adhesive protein comprising an amphiphilic peptide at the carbon or amine terminal of the protein, enabling homogeneous dispersion of several materials in various solvents and coating of the homogeneously dispersed particles on a hydrophilic or hydrophobic surface, particularly the homogeneous dispersion of hydrophilic or hydrophobic particles in a hydrophobic or hydrophilic solvent on the basis of strong adhesive strength of a mussel adhesive protein; the surface adhesive protein can be used as a surface coating agent requiring antibacterial or antiviral functions as well as a cosmetic product or an ink.Type: GrantFiled: August 8, 2016Date of Patent: December 22, 2020Assignee: KOLLODIS BIOSCIENCES, INC.Inventors: Sang Jae Lee, Bong Jin Hong
-
Patent number: 10858389Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.Type: GrantFiled: March 25, 2016Date of Patent: December 8, 2020Assignee: Amgen Inc.Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
-
Patent number: 10844094Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) fconstituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.Type: GrantFiled: August 21, 2018Date of Patent: November 24, 2020Assignees: TECHNISCHE UNIVERSITÄT MÜNCHEN, XL-PROTEIN GMBHInventors: Arne Skerra, Uli Binder, Martin Schlapschy
-
Patent number: 10844090Abstract: Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W1, W4, W5, SG, and R are as described herein.Type: GrantFiled: January 29, 2016Date of Patent: November 24, 2020Assignee: SUTRO BIOPHARMA, INC.Inventors: Toni Kline, Qun Yin, Krishna Bajjuri
-
Patent number: 10844093Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.Type: GrantFiled: August 7, 2019Date of Patent: November 24, 2020Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Patent number: 10835579Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.Type: GrantFiled: August 25, 2015Date of Patent: November 17, 2020Assignee: INVEX THERAPEUTICS LTD.Inventor: Alex Sinclair
-
Patent number: 10829530Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.Type: GrantFiled: June 25, 2019Date of Patent: November 10, 2020Assignees: B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. BEN-GURION UNIVERSITY OF THE NEGEVInventor: Varda Shoshan-Barmatz
-
Patent number: 10821136Abstract: The present invention provides a bone formation promoter having high biological safety and capable of promoting bone formation. The bone formation promoter of the present invention includes a self-assembling peptide capable of forming a ?-sheet structure in an aqueous solution having a neutral pH; and a bone chip. A sum of charges of amino acid residues constituting the self-assembling peptide at pH 7.0 is unequal to 0.Type: GrantFiled: June 29, 2015Date of Patent: November 3, 2020Assignees: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM, MENICON CO., LTD.Inventors: Kei Ando, Naoki Ishiguro, Shiro Imagama, Zenya Ito, Yasuhiro Yokoyama, Hidenori Yokoi, Yusuke Nagai
-
Patent number: 10822388Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.Type: GrantFiled: May 1, 2017Date of Patent: November 3, 2020Assignee: University Health NetworkInventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin